Ex vivo analysis of tumor antigen specific CD8+ T cell responses using MHC/peptide tetramers in cancer patients

Altman, 1996, Phenotypic analysis of antigen-specific T lymphocytes, Science, 274, 94, 10.1126/science.274.5284.94 McMichael, 1998, A new look at T cells, J. Exp. Med., 187, 1367, 10.1084/jem.187.9.1367 Crawford, 1998, Detection of antigen-specific T cells with multivalent soluble class II MHC covalent peptide complexes, Immunity, 8, 675, 10.1016/S1074-7613(00)80572-5 Gutgemann, 1998, Induction of rapid T cell activation and tolerance by systemic presentation of an orally administered antigen, Immunity, 8, 667, 10.1016/S1074-7613(00)80571-3 Rees, 1999, An inverse relationship between T cell receptor affinity and antigen dose during CD4(+) T cell responses in vivo and in vitro, Proc. Natl. Acad. Sci. U. S. A., 96, 9781, 10.1073/pnas.96.17.9781 Savage, 1999, A kinetic basis for T cell receptor repertoire selection during an immune response, Immunity, 10, 485, 10.1016/S1074-7613(00)80048-5 Kuroda, 2000, Human immunodeficiency virus type 1 envelope epitope-specific CD4(+) T lymphocytes in simian/human immunodeficiency virus-infected and vaccinated rhesus monkeys detected using a peptide-major histocompatibility complex class II tetramer, J. Virol., 74, 8751, 10.1128/JVI.74.18.8751-8756.2000 Cochran, 2000, The relationship of MHC-peptide binding and T cell activation probed using chemically defined MHC class II oligomers, Immunity, 12, 241, 10.1016/S1074-7613(00)80177-6 Kotzin, 2000, Use of soluble peptide-DR4 tetramers to detect synovial T cells specific for cartilage antigens in patients with rheumatoid arthritis, Proc. Natl. Acad. Sci. U. S. A., 97, 291, 10.1073/pnas.97.1.291 Novak, 1999, MHC class II tetramers identify peptide-specific human CD4(+) T cells proliferating in response to influenza A antigen, J. Clin. Invest., 104, R63, 10.1172/JCI8476 Kwok, 2000, HLA-DQ tetramers identify epitope-specific T cells in peripheral blood of herpes simplex virus type 2-infected individuals: direct detection of immunodominant antigen-responsive cells, J. Immunol., 164, 4244, 10.4049/jimmunol.164.8.4244 Matsuda, 2000, Tracking the response of natural killer T cells to a glycolipid antigen using CD1d tetramers, J. Exp. Med., 192, 741, 10.1084/jem.192.5.741 Braud, 1998, HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C, Nature, 391, 795, 10.1038/35869 Lepin, 2000, Functional characterization of HLA-F and binding of HLA-F tetramers to ILT2 and ILT4 receptors, Eur. J. Immunol., 30, 3552, 10.1002/1521-4141(200012)30:12<3552::AID-IMMU3552>3.0.CO;2-L Romero, 1998, Ex vivo staining of metastatic lymph nodes by class I major histocompatibility complex tetramers reveals high numbers of antigen-experienced tumor-specific cytolytic T lymphocytes, J. Exp. Med., 188, 1641, 10.1084/jem.188.9.1641 Pittet, 1999, High frequencies of naive Melan-A/MART-1-specific CD8(+) T cells in a large proportion of human histocompatibility leukocyte antigen (HLA)-A2 individuals, J. Exp. Med., 190, 705, 10.1084/jem.190.5.705 Bodinier, 2000, Efficient detection and immunomagnetic sorting of specific T cells using multimers of MHC class I and peptide with reduced CD8 binding, Nat. Med., 6, 707, 10.1038/76292 Brunner, 1968, Quantitative assay of the lytic action of immune lymphoid cells on 51-Cr-labelled allogeneic target cells in vitro; inhibition by isoantibody and by drugs, Immunology, 14, 181 Moretta, 1983, Quantitative assessment of the pool size and subset distribution of cytolytic T lymphocytes within human resting or alloactivated peripheral blood T cell populations, J. Exp. Med., 158, 571, 10.1084/jem.158.2.571 Taswell, 1981, Limiting dilution assays for the determination of immunocompetent cell frequencies: I. Data analysis, J. Immunol., 126, 1614, 10.4049/jimmunol.126.4.1614 van Oers, 1978, Quantification of antigen-reactive cells among human T lymphocytes, Eur. J. Immunol., 8, 477, 10.1002/eji.1830080706 Green, 1994, Activation-induced apoptosis in lymphocytes, Curr. Opin. Immunol., 6, 476, 10.1016/0952-7915(94)90130-9 Kuzushima, 1999, Rapid determination of Epstein–Barr virus-specific CD8(+) T-cell frequencies by flow cytometry, Blood, 94, 3094, 10.1182/blood.V94.9.3094 Tan, 1999, A re-evaluation of the frequency of CD8+ T cells specific for EBV in healthy virus carriers, J. Immunol., 162, 1827, 10.4049/jimmunol.162.3.1827 Czerkinsky, 1988, Reverse ELISPOT assay for clonal analysis of cytokine production. I. Enumeration of gamma-interferon-secreting cells, J. Immunol. Methods, 110, 29, 10.1016/0022-1759(88)90079-8 Jager, 2000, Monitoring CD8 T cell responses to NY-ESO-1: correlation of humoral and cellular immune responses, Proc. Natl. Acad. Sci. U. S. A., 97, 4760, 10.1073/pnas.97.9.4760 Scheibenbogen, 2000, Quantitation of antigen-reactive T cells in peripheral blood by IFNgamma-ELISPOT assay and chromium-release assay: a four-centre comparative trial, J. Immunol. Methods, 244, 81, 10.1016/S0022-1759(00)00257-X Lee, 1999, Increased vaccine-specific T cell frequency after peptide-based vaccination correlates with increased susceptibility to in vitro stimulation but does not lead to tumor regression, J. Immunol., 163, 6292, 10.4049/jimmunol.163.11.6292 Maino, 1998, Identification of functional subsets by flow cytometry: intracellular detection of cytokine expression, Cytometry, 34, 207, 10.1002/(SICI)1097-0320(19981015)34:5<207::AID-CYTO1>3.0.CO;2-J Waldrop, 1997, Determination of antigen-specific memory/effector CD4+ T cell frequencies by flow cytometry: evidence for a novel, antigen-specific homeostatic mechanism in HIV-associated immunodeficiency, J. Clin. Invest., 99, 1739, 10.1172/JCI119338 Brosterhus, 1999, Enrichment and detection of live antigen-specific CD4(+) and CD8(+) T cells based on cytokine secretion, Eur. J. Immunol., 29, 4053, 10.1002/(SICI)1521-4141(199912)29:12<4053::AID-IMMU4053>3.0.CO;2-C Dutton, 1998, T cell memory, Annu. Rev. Immunol., 16, 201, 10.1146/annurev.immunol.16.1.201 Lee, 1999, Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients, Nat. Med., 5, 677, 10.1038/9525 Valitutti, 1995, Serial triggering of many T-cell receptors by a few peptide-MHC complexes, Nature, 375, 148, 10.1038/375148a0 Appay, 2000, HIV-specific CD8(+) T cells produce antiviral cytokines but are impaired in cytolytic function, J. Exp. Med., 192, 63, 10.1084/jem.192.1.63 Pittet, 2001, Expansion and functional maturation of human tumor antigen-specific CD8+ T cells following vaccination with antigenic peptide, Clin. Cancer Res. Valmori, 2000, Tetramer-guided analysis of TCR beta-chain usage reveals a large repertoire of melan-A-specific CD8+ T cells in melanoma patients, J. Immunol., 165, 533, 10.4049/jimmunol.165.1.533 Rimoldi, 2000, Efficient simultaneous presentation of NY-ESO-1/LAGE-1 primary and nonprimary open reading frame-derived CTL epitopes in melanoma, J. Immunol., 165, 7253, 10.4049/jimmunol.165.12.7253 Yee, 1999, Isolation of high avidity melanoma-reactive CTL from heterogeneous populations using peptide-MHC tetramers, J. Immunol., 162, 2227, 10.4049/jimmunol.162.4.2227 Gervois, 2000, High avidity melanoma-reactive cytotoxic T lymphocytes are efficiently induced from peripheral blood lymphocytes on stimulation by peptide-pulsed melanoma cells, Clin. Cancer Res., 6, 1459 Oelke, 2000, Generation and purification of CD8+ melan-A-specific cytotoxic T lymphocytes for adoptive transfer in tumor immunotherapy, Clin. Cancer Res., 6, 1997 Valmori, 1999, An antigen-targeted approach to adoptive transfer therapy of cancer, Cancer Res., 59, 2167 Yee, 2000, Melanocyte destruction after antigen-specific immunotherapy of melanoma, Direct evidence of T cell-mediated vitiligo, J. Exp. Med., 192, 1637, 10.1084/jem.192.11.1637 Robbins, 1996, Human tumor antigens recognized by T cells, Curr. Opin. Immunol., 8, 628, 10.1016/S0952-7915(96)80078-1 Romero, 1996, Cytolytic T lymphocyte responses of cancer patients to tumor-associated antigens, Springer Semin. Immunopathol., 18, 185, 10.1007/BF00820665 Valmori, 1999, Analysis of the cytolytic T lymphocyte response of melanoma patients to the naturally HLA-A*0201-associated tyrosinase peptide 368–376, Cancer Res., 59, 4050 Valmori, 2000, Naturally occurring HLA-A2 restricted CD8+ T cell response to the cancer testis antigen NY-ESO-1 in melanoma patients, Cancer Res., 60, 4499 Coulie, 1994, A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas, J. Exp. Med., 180, 35, 10.1084/jem.180.1.35 Kawakami, 1994, Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor, Proc. Natl. Acad. Sci. U. S. A., 91, 3515, 10.1073/pnas.91.9.3515 Kawakami, 1994, Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes, J. Exp. Med., 180, 347, 10.1084/jem.180.1.347 Romero, 1997, Cytolytic T lymphocyte recognition of the immunodominant HLA-A*0201-restricted Melan-A/MART-1 antigenic peptide in melanoma, J. Immunol., 159, 2366, 10.4049/jimmunol.159.5.2366 Valmori, 1998, Enhanced generation of specific tumor-reactive CTL in vitro by selected Melan-A/MART-1 immunodominant peptide analogues, J. Immunol., 160, 1750, 10.4049/jimmunol.160.4.1750 Anichini, 1999, J. Exp. Med., 190, 651, 10.1084/jem.190.5.651 Dunbar, 2000, A shift in the phenotype of melan-A-specific CTL identifies melanoma patients with an active tumor-specific immune response, J. Immunol., 165, 6644, 10.4049/jimmunol.165.11.6644 Aarnoudse, 1999, Interleukin-2-induced, melanoma-specific T cells recognize CAMEL, an unexpected translation product of LAGE-1, Int. J. Cancer, 82, 442, 10.1002/(SICI)1097-0215(19990730)82:3<442::AID-IJC19>3.0.CO;2-Z De Plaen, 1994, Structure, chromosomal localization, and expression of 12 genes of the MAGE family, Immunogenetics, 40, 360, 10.1007/BF01246677 Huang, 1999, Cytolytic T lymphocytes recognize an antigen encoded by MAGE-A10 on a human melanoma, J. Immunol., 162, 6849, 10.4049/jimmunol.162.11.6849 Valmori, 2001, Frequent cytolytic T-cell responses to peptide MAGE-A10 254–262 in melanoma, Cancer Res., 61, 509 Baurain, 2000, High frequency of autologous anti-melanoma CTL directed against an antigen generated by a point mutation in a new helicase gene, J. Immunol., 164, 6057, 10.4049/jimmunol.164.11.6057 Brash, 1991, A role for sunlight in skin cancer: UV-induced p53 mutations in squamous cell carcinoma, Proc. Natl. Acad. Sci. U. S. A., 88, 10124, 10.1073/pnas.88.22.10124 Vonderheide, 1999, The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes, Immunity, 10, 673, 10.1016/S1074-7613(00)80066-7 Greider, 1996, Telomere length regulation, Annu. Rev. Biochem., 65, 337, 10.1146/annurev.bi.65.070196.002005 Minev, 2000, Cytotoxic T cell immunity against telomerase reverse transcriptase in humans, Proc. Natl. Acad. Sci. U. S. A., 97, 4796, 10.1073/pnas.070560797 Youde, 2000, Use of fluorogenic histocompatibility leukocyte antigen-A*0201/HPV 16 E7 peptide complexes to isolate rare human cytotoxic T-lymphocyte-recognizing endogenous human papillomavirus antigens, Cancer Res., 60, 365 Molldrem, 1999, A PR1-human leukocyte antigen-A2 tetramer can be used to isolate low-frequency cytotoxic T lymphocytes from healthy donors that selectively lyse chronic myelogenous leukemia, Cancer Res., 59, 2675 Molldrem, 2000, Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia, Nat. Med., 6, 1018, 10.1038/79526 Marchand, 1999, Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1, Int. J. Cancer, 80, 219, 10.1002/(SICI)1097-0215(19990118)80:2<219::AID-IJC10>3.0.CO;2-S Thurner, 1999, Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma, J. Exp. Med., 190, 1669, 10.1084/jem.190.11.1669 Cormier, 1997, Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1/Melan A, Cancer J. Sci. Am., 3, 37 Salgaller, 1996, Immunization against epitopes in the human melanoma antigen gp100 following patient immunization with synthetic peptides, Cancer Res., 56, 4749 Rosenberg, 1998, Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma, Nat. Med., 4, 321, 10.1038/nm0398-321 Nielsen, 2000, Status of activation of circulating vaccine-elicited CD8+ T cells, J. Immunol., 165, 2287, 10.4049/jimmunol.165.4.2287 Panelli, 2000, Expansion of tumor-T cell pairs from fine needle aspirates of melanoma metastases, J. Immunol., 164, 495, 10.4049/jimmunol.164.1.495 Fuchs, 1996, Is cancer dangerous to the immune system?, Semin. Immunol., 8, 271, 10.1006/smim.1996.0035 Becker, 2000, Differential expression of CD28 and CD94/NKG2 on T cells with identical TCR beta variable regions in primary melanoma and sentinel lymph node, Eur. J. Immunol., 30, 3699, 10.1002/1521-4141(200012)30:12<3699::AID-IMMU3699>3.0.CO;2-2 Speiser, 1999, In vivo expression of natural killer cell inhibitory receptors by human melanoma-specific cytolytic T lymphocytes, J. Exp. Med., 190, 775, 10.1084/jem.190.6.775 Guerra, 2000, Killer inhibitory receptor (CD158b) modulates the lytic activity of tumor-specific T lymphocytes infiltrating renal cell carcinomas, Blood, 95, 2883, 10.1182/blood.V95.9.2883.009k22_2883_2889 Ferrone, 1995, Loss of HLA class I antigens by melanoma cells: molecular mechanisms, functional significance and clinical relevance, Immunol. Today, 16, 487, 10.1016/0167-5699(95)80033-6 Cormier, 1998, Heterogeneous expression of melanoma-associated antigens and HLA-A2 in metastatic melanoma in vivo, Int. J. Cancer, 75, 517, 10.1002/(SICI)1097-0215(19980209)75:4<517::AID-IJC5>3.0.CO;2-W de Vries, 1997, Heterogeneous expression of immunotherapy candidate proteins gp100, MART-1, and tyrosinase in human melanoma cell lines and in human melanocytic lesions, Cancer Res., 57, 3223 Jager, 1996, Inverse relationship of melanocyte differentiation antigen expression in melanoma tissues and CD8+ cytotoxic-T-cell responses: evidence for immunoselection of antigen-loss variants in vivo, Int. J. Cancer, 66, 470, 10.1002/(SICI)1097-0215(19960516)66:4<470::AID-IJC10>3.0.CO;2-C Mizoguchi, 1992, Alterations in signal transduction molecules in T lymphocytes from tumor-bearing mice, Science, 258, 1795, 10.1126/science.1465616 Hahne, 1996, Melanoma cell expression of Fas(Apo-1/CD95) ligand: implications for tumor immune escape, Science, 274, 1363, 10.1126/science.274.5291.1363 Speiser, 2001, Human CD8+ T cells expressing HLA-DR and CD28 show telomerase activity and are distinct from cytolytic effector T cells, Eur. J. Immunol., 31, 459, 10.1002/1521-4141(200102)31:2<459::AID-IMMU459>3.0.CO;2-Y Azuma, 1993, CD28-T lymphocytes. Antigenic and functional properties, J. Immunol., 150, 1147, 10.4049/jimmunol.150.4.1147 Hamann, 1999, Faces and phases of human CD8 T-cell development, Immunol. Today, 20, 177, 10.1016/S0167-5699(99)01444-9 Wang, 1997, CD8high+ (CD57+) T cells in patients with rheumatoid arthritis, Arthritis Rheum., 40, 237, 10.1002/art.1780400208 Pittet, 2000, Cutting edge: cytolytic effector function in human circulating CD8+ T cells closely correlates with CD56 surface expression, J. Immunol., 164, 1148, 10.4049/jimmunol.164.3.1148 Haanen, 2000, In situ detection of virus- and tumor-specific T-cell immunity, Nat. Med., 6, 1056, 10.1038/79573 Skinner, 2000, Cutting edge: in situ tetramer staining of antigen-specific T cells in tissues, J. Immunol., 165, 613, 10.4049/jimmunol.165.2.613 Speiser, 1997, Self antigens expressed by solid tumors Do not efficiently stimulate naive or activated T cells: implications for immunotherapy, J. Exp. Med., 186, 645, 10.1084/jem.186.5.645 Callan, 1998, Direct visualization of antigen-specific CD8+ T cells during the primary immune response to Epstein–Barr virus In vivo, J. Exp. Med., 187, 1395, 10.1084/jem.187.9.1395 Murali-Krishna, 1998, Counting antigen-specific CD8 T cells: a reevaluation of bystander activation during viral infection, Immunity, 8, 177, 10.1016/S1074-7613(00)80470-7 Zinkernagel, 1997, Antiviral immunity, Immunol. Today, 18, 258, 10.1016/S0167-5699(97)80017-5 Chen, 2000, Identification of NY-ESO-1 peptide analogues capable of improved stimulation of tumor-reactive CTL, J. Immunol., 165, 948, 10.4049/jimmunol.165.2.948 Romero, 2001, CD8+ T cell response to NY-ESO-1: relative antigenicity and in vitro immunogenicity of natural and analogue sequences, Clin. Cancer Res.